Shots:

• The IDMC has recommended the discontinuation of the P-III CHAMPION-ALS trial for Ultomiris (IV- q8w) in adults with ALS. Additionally- enrolled patients will discontinue the study medication and complete any required follow-up assessment
• The discontinuation is due to lack of efficacy based on the pre-specified interim analysis. No new safety was identified while the results were consistent with the established safety profile of Ultomiris
• Ultomiris is the 1st long-acting C5 complement inhibitor & is approved in the US- EU & Japan for PNH & aHUS in adults and children aged ≥1mos.

  | Ref: Astrazeneca | Image: Astrazeneca